Terazosin NDC 27241-291

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-291Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0291Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-291-01	27241029101	100 CAPSULE in 1 BOTTLE (27241-291-01)Marketed from May 12, 2025
27241-291-10	27241029110	1000 CAPSULE in 1 BOTTLE (27241-291-10)Marketed from May 12, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Terazosin
Generic name (nonproprietary): terazosin
Active ingredients: Terazosin hydrochloride — 10 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219482
Marketing start: May 12, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 27241-291_ec1b00c3-3d59-420a-a71c-e9bd9a8d02fdSPL ID ec1b00c3-3d59-420a-a71c-e9bd9a8d02fdSPL set ID bed99c2a-4266-4a2c-bb0f-7643fdafff78RxCUI 260376, 313215, 313217, 313219UNII D32S14F082UPC 0327241289019, 0327241291012, 0327241290015, 0327241288012
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241029101 followed by a unit qualifier and the quantity

Package 27241-0291-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 24, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules. The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219482

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219482
Product	Strength	Form · route	Labeler	Product NDC
Terazosin	Terazosin hydrochloride 1 mg/1	CapsuleOral	Ajanta Pharma USA Inc.	27241-288
Terazosin	Terazosin hydrochloride 2 mg/1	CapsuleOral	Ajanta Pharma USA Inc.	27241-289
Terazosin	Terazosin hydrochloride 5 mg/1	CapsuleOral	Ajanta Pharma USA Inc.	27241-290